IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Stifel Financial Corp

Stifel Financial Corp decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 20.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,723 shares of the company’s stock after selling 6,893 shares during the quarter. Stifel Financial Corp’s holdings in IDEXX Laboratories were worth $11,048,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of IDXX. Hurley Capital LLC bought a new position in IDEXX Laboratories in the 4th quarter worth about $29,000. Rialto Wealth Management LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $30,000. Retirement Wealth Solutions LLC bought a new position in IDEXX Laboratories in the 4th quarter worth approximately $31,000. Kestra Investment Management LLC acquired a new stake in IDEXX Laboratories in the 4th quarter valued at approximately $38,000. Finally, Crews Bank & Trust bought a new stake in IDEXX Laboratories during the 4th quarter valued at $41,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

NASDAQ IDXX opened at $411.72 on Friday. The company has a market cap of $33.37 billion, a P/E ratio of 38.59, a P/E/G ratio of 3.41 and a beta of 1.50. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $548.88. The company has a fifty day simple moving average of $422.37 and a 200 day simple moving average of $430.84.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on IDXX shares. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 12th. Stifel Nicolaus decreased their price objective on shares of IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating for the company in a report on Monday, April 14th. Morgan Stanley dropped their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Barclays lifted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Finally, Piper Sandler upped their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average price target of $523.75.

Insiders Place Their Bets

In related news, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.